Bladder cancer

S1806

SWOG/NRG Joint Study: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive

Trial overview

Topic

S1806

Disease

Bladder cancer treatment and diagnosis

Description

Primary Objective:To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).Patient Population:Patients with muscle invasive bladder cancer (MIBC) (T2-T4aN0M0).

Contact

Michigan

Maria Pappas

Physicians

Thomas Boike

MD

Radiation Oncologist

Clarkston (Radiation oncology) +3

Larry L. Kestin

MD, FACR, FASTRO

Radiation Oncologist

Farmington Hills (Radiation oncology) +2

Alvaro A. Martinez

MD, FACR, FABS, FASTRO

Radiation Oncologist

Pontiac (Radiation oncology) +4

Frank A. Vicini

MD, FACR, FASTRO, FABS

Radiation Oncologist

Farmington Hills (Radiation oncology) +2

John Vito Antonucci

MD

Radiation Oncologist

Madison Heights (Radiation oncology) +3

Michael I. Ghilezan

MD, PhD

Radiation Oncologist

Pontiac (Radiation oncology) +3